GDF15 and idiopathic pulmonary arterial hypertension: Study identifies GDF15 as a biomarker—accurately distinguishing PVOD from other PAH forms and predicting outcomes across PVOD, IPAH, and HPAH—advancing earlier diagnosis and personalized treatment.